BACKGROUND: Congestive heart failure (CHF) features disturbances in the interstitial environment that may affect the accuracy of subcutaneous continuous glucose monitoring (CGM). SUBJECTS AND METHODS: A pooled analysis of two studies of hospitalized patients with type 2 diabetes randomized to intravenous or subcutaneous insulin was conducted. One study enrolled patients with CHF exacerbation, whereas history of CHF was an exclusion criterion in the other. All patients wore a professional CGM device for at least 24 h. Intravenous insulin was administered according to the institution's nursing-run protocol (duration of 12 and 48 h in non-CHF and CHF protocols, respectively). Subcutaneous insulin was delivered similarly in both groups. RESULTS:Subjects with CHF (n=43) hadhigher admission glucose and hemoglobin A1c compared with non-CHF subjects (n=32), but the sensor glucose values were similar. Overall mean absolute relative difference (MARD) was similar between CHF and non-CHF subjects (0.11 vs. 0.08, respectively; P=0.12). MARD was higher in the 100-149 mg/dL (P=0.003) and >199 mg/dL (P = 0.02) strata among CHF subjects. Static glucose and continuous glucose error grid analyses favored the non-CHF group. In multivariable analyses, only glucose coefficient of variation and log sensor time were independent predictors of elevated overall MARD >0.10. After adjustment for other factors, only increasing log sensor time was a significant predictor of elevated MARD in the 100-149 mg/dL strata. CONCLUSIONS: Among hospitalized subjects with type 2 diabetes, CHF exacerbation is not associated with lower sensor accuracy after adjustment for other factors, but this requires confirmation over a wider glucose range.
RCT Entities:
BACKGROUND:Congestive heart failure (CHF) features disturbances in the interstitial environment that may affect the accuracy of subcutaneous continuous glucose monitoring (CGM). SUBJECTS AND METHODS: A pooled analysis of two studies of hospitalized patients with type 2 diabetes randomized to intravenous or subcutaneous insulin was conducted. One study enrolled patients with CHF exacerbation, whereas history of CHF was an exclusion criterion in the other. All patients wore a professional CGM device for at least 24 h. Intravenous insulin was administered according to the institution's nursing-run protocol (duration of 12 and 48 h in non-CHF and CHF protocols, respectively). Subcutaneous insulin was delivered similarly in both groups. RESULTS: Subjects with CHF (n=43) had higher admission glucose and hemoglobin A1c compared with non-CHF subjects (n=32), but the sensor glucose values were similar. Overall mean absolute relative difference (MARD) was similar between CHF and non-CHF subjects (0.11 vs. 0.08, respectively; P=0.12). MARD was higher in the 100-149 mg/dL (P=0.003) and >199 mg/dL (P = 0.02) strata among CHF subjects. Static glucose and continuous glucose error grid analyses favored the non-CHF group. In multivariable analyses, only glucose coefficient of variation and log sensor time were independent predictors of elevated overall MARD >0.10. After adjustment for other factors, only increasing log sensor time was a significant predictor of elevated MARD in the 100-149 mg/dL strata. CONCLUSIONS: Among hospitalized subjects with type 2 diabetes, CHF exacerbation is not associated with lower sensor accuracy after adjustment for other factors, but this requires confirmation over a wider glucose range.
Authors: Philip A Goldberg; Mark D Siegel; Raymond R Russell; Robert S Sherwin; Joshua I Halickman; Dawn A Cooper; James D Dziura; Silvio E Inzucchi Journal: Diabetes Technol Ther Date: 2004-06 Impact factor: 6.118
Authors: Hannah G Piper; Jamin L Alexander; Avinash Shukla; Frank Pigula; John M Costello; Peter C Laussen; Tom Jaksic; Michael S D Agus Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: Salmaan Kanji; Jennifer Buffie; Brian Hutton; Peter S Bunting; Avinder Singh; Kevin McDonald; Dean Fergusson; Lauralyn A McIntyre; Paul C Hebert Journal: Crit Care Med Date: 2005-12 Impact factor: 7.598
Authors: Paul R Kalra; Constantinos Anagnostopoulos; Aidan P Bolger; Andrew J S Coats; Stefan D Anker Journal: J Am Coll Cardiol Date: 2002-06-19 Impact factor: 24.094
Authors: Anouk M Corstjens; Jack J M Ligtenberg; Iwan C C van der Horst; Rob Spanjersberg; Joline S W Lind; Jaap E Tulleken; John H J M Meertens; Jan G Zijlstra Journal: Crit Care Date: 2006 Impact factor: 9.097